Decreased expression of protease-activated receptor 4 in human gastric cancer.

Protease-activated receptors (PARs) are a unique family of G-protein coupled receptors. PAR4, the most recently identified PAR member, was reported to be overexpressed during the progression of colon and prostate cancers. Though PAR4 mRNA was detected in normal stomach, the role of PAR4 in gastric cancer has not been investigated. In this study, differential expression of PAR4 was measured by real-time PCR (n=28) and tissue microarrays (n=74). We showed that PAR4 was located from basal to middle portions of normal gastric mucosa. PAR4 expression was remarkably decreased in gastric cancer tissues as compared with matched noncancerous tissues, especially in positive lymph node or low differentiation cancers. Furthermore, methylation of the PAR4 promoter in cell lines was assessed by treatment with 5-aza-2'-deoxycytidine and genomic bisulfite sequencing. AGS and N87 human gastric cancer cell lines did not express PAR4, as compared to HT-29 human colon cancer cell line with significant PAR4 expression. Treatment with 5-aza-2'-deoxycytidine restored PAR4 expression in AGS and N87 cells, which exhibited significantly more 5-methylcytosines in the PAR4 promoter compared with HT-29 cells. Our results revealed that down-regulation of PAR4 expression occurs frequently in gastric cancers and exhibits association with more aggressive gastric cancer. Interestingly, the loss of PAR4 expression in gastric cancers may result from hypermethylation of the PAR4 promoter.

[1]  M. Rugge,et al.  p53 alteration in gastric precancerous lesions. , 1994, The American journal of pathology.

[2]  Jiang He,et al.  Major causes of death among men and women in China. , 2005, The New England journal of medicine.

[3]  M. Laburthe,et al.  Aberrant expression of proteinase‐activated receptor 4 promotes colon cancer cell proliferation through a persistent signaling that involves Src and ErbB‐2 kinase , 2009, International journal of cancer.

[4]  Thomas Werner,et al.  MatInspector and beyond: promoter analysis based on transcription factor binding sites , 2005, Bioinform..

[5]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[6]  R. Tavares,et al.  Decreased Expression of Gastrokine 1 and the Trefoil Factor Interacting Protein TFIZ1/GKN2 in Gastric Cancer: Influence of Tumor Histology and Relationship to Prognosis , 2008, Clinical Cancer Research.

[7]  C. Cass,et al.  Gastric Cancer: Establishing Predictors of Biologic Behavior with Use of Population-Based Data , 2004, Annals of Surgical Oncology.

[8]  L. Schmidt,et al.  A novel germ line juxtamembrane Met mutation in human gastric cancer , 2000, Oncogene.

[9]  Mitsuru Sasako,et al.  Focus on gastric cancer. , 2004, Cancer cell.

[10]  Yun Zhang,et al.  Melanoma cell growth inhibition by betagamma-CAT, which is a novel non-lens betagamma-crystallin and trefoil factor complex from frog Bombina maxima skin. , 2008, Toxicon : official journal of the International Society on Toxinology.

[11]  H. Höfler,et al.  E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. , 1994, Cancer research.

[12]  Jun Yu,et al.  Loss of beta-catenin expression in metastatic gastric cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Reiser,et al.  Thrombin Signaling in the Brain: The Role of Protease-Activated Receptors , 2003, Biological chemistry.

[14]  M. Hollenberg,et al.  Thrombin‐mediated hepatocellular carcinoma cell migration: Cooperative action via proteinase‐activated receptors 1 and 4 , 2007, Journal of cellular physiology.

[15]  H. Allgayer,et al.  c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  I. Petersen,et al.  Expression of proteinase-activated receptor 1-4 (PAR 1-4) in human cancer , 2010, Journal of Molecular Histology.

[17]  S. Coughlin,et al.  Thrombin signalling and protease-activated receptors , 2000, Nature.

[18]  J. Siewert,et al.  Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. , 1998, Annals of surgery.

[19]  S. Coughlin,et al.  Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. , 2004, Blood.

[20]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[21]  Yasuo Ohashi,et al.  Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer , 2009 .

[22]  M. Steinhoff,et al.  Proteinase-activated receptor-2 (PAR2): a tumor suppressor in skin carcinogenesis. , 2007, The Journal of investigative dermatology.

[23]  R. Vessella,et al.  Overexpression of protease‐activated receptors‐1,‐2, and‐4 (PAR‐1, ‐2, and ‐4) in prostate cancer , 2007, The Prostate.

[24]  N. Vergnolle,et al.  CLINICAL RELEVANCE OF PROTEINASE ACTIVATED RECEPTORS (PARS) IN THE GUT , 2005, Gut.

[25]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[26]  A. Kawabata,et al.  Gastrointestinal roles for proteinase‐activated receptors in health and disease , 2008, British journal of pharmacology.

[27]  Scott R. Presnell,et al.  Cloning and characterization of human protease-activated receptor 4. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  R. Lai,et al.  A Novel Non-Lens βγ−Crystallin and Trefoil Factor Complex from Amphibian Skin and Its Functional Implications , 2008, PloS one.

[29]  H. Otani,et al.  Proteinase-activated receptor 4 stimulation-induced epithelial-mesenchymal transition in alveolar epithelial cells , 2007, Respiratory research.

[30]  P. Rosenberg,et al.  Age-specific trends in incidence of noncardia gastric cancer in US adults. , 2010, JAMA.

[31]  M. Laburthe,et al.  Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. , 2003, The American journal of pathology.

[32]  A. Agarwal,et al.  PAR1 Is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells , 2005, Cell.

[33]  J. Gutkind,et al.  G-protein-coupled receptors and cancer , 2007, Nature Reviews Cancer.

[34]  Y. Daaka.  G Proteins in Cancer: The Prostate Cancer Paradigm , 2004, Science's STKE.

[35]  N. Bunnett,et al.  Protease-activated receptors: contribution to physiology and disease. , 2004, Physiological reviews.

[36]  M. Steinhoff,et al.  Protease-activated receptors: novel PARtners in innate immunity. , 2007, Trends in immunology.

[37]  Reuven Reich,et al.  Thrombin receptor overexpression in malignant and physiological invasion processes , 1998, Nature Medicine.

[38]  J. McDougall,et al.  Triggering of proteinase-activated receptor 4 leads to joint pain and inflammation in mice. , 2009, Arthritis and rheumatism.